What Does NSG Mean in Medical Terms?

NSG carries at least three distinct meanings in medical and biomedical literature, and the correct one depends entirely on context. In laboratory research papers, NSG almost always refers to a highly immunodeficient mouse strain used for transplanting human cells and tissues into living animals. In neonatal radiology, NSG is shorthand for neurosonography, an ultrasound-based technique for imaging infant brains. And in pulmonary pathology, NSG stands for necrotizing sarcoid granulomatosis, a rare lung disease that can mimic both infections and cancer. Because the mouse strain dominates the published literature by volume, that is typically the meaning a reader encounters first.

The NSG Mouse Strain

When researchers write “NSG mice,” they mean a specific line of laboratory mice bred to have virtually no functioning immune system. The full designation is NOD/SCID/IL-2Rγ-null, sometimes written out as NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ. Each part of that name reflects a genetic feature that disables a different arm of immunity. The NOD background refers to the non-obese diabetic strain, which already has weakened innate immune cells. The SCID mutation knocks out the ability to produce functional T cells and B cells. And the deletion of the IL-2 receptor gamma chain eliminates natural killer cells, the last major line of immune defense. Together, these three hits create a mouse with so little immune surveillance that it readily accepts foreign human cells without rejecting them.

This strain is widely described as the most commonly used immunodeficient mouse for xenograft transplantation, meaning the grafting of human tissue into a non-human host.¹ The reason is straightforward: human cells survive and grow in these animals in ways that are impossible in mice with even partial immunity. That property has made NSG mice the backbone of several major research fields.

Why NSG Mice Matter in Cancer Research

One of the biggest applications is building patient-derived xenograft (PDX) models for cancer. In a PDX study, a surgeon removes a piece of a patient’s tumor and implants it into an NSG mouse. Because the mouse cannot mount an immune response against the foreign tissue, the tumor engrafts and grows. Researchers can then test drugs on a living tumor that retains the genetic complexity of the original cancer, rather than relying on cell lines grown in a dish for decades. Studies have found that NSG mice engraft tumors at higher rates than older immunodeficient strains, and that the tumor’s genetic diversity is preserved through multiple passages.² Perhaps more importantly, the way tumors in these models respond to therapy appears to mirror how the original patient’s cancer responded, making them a potentially valuable bridge between lab experiments and clinical trials.

This engraftment advantage is not trivial. Older mouse strains like the athymic nude mouse or the beige-scid mouse retain some residual immune activity, which means a significant fraction of implanted human tumors simply get destroyed before they can establish themselves. NSG mice eliminate that problem by removing the last immune barrier, natural killer cells, that those older models still possessed.

NSG Mice in Stem Cell and Immune System Research

Beyond cancer, NSG mice are central to the study of human blood-forming stem cells. Researchers inject purified human stem cells, typically CD34-positive cells isolated from umbilical cord blood or other sources, into irradiated NSG mice. The human cells then colonize the mouse’s bone marrow and begin producing human blood and immune cells. This “humanized” mouse carries a functioning (though imperfect) human immune system inside a mouse body, allowing scientists to study human immune responses in a living organism without experimenting on people.

Both fetal liver and cord blood stem cells can successfully rebuild human immune lineages in NSG mice.³ Interestingly, the sex of the mouse matters: female NSG mice are substantially better at detecting and supporting human stem cells than males.⁴ This is not a minor quirk. A stem cell preparation that looks weak in male mice might look robust in females, which means the choice of recipient sex can change the conclusions of an experiment.

These humanized NSG mice have become especially important in HIV research. Because HIV infects human immune cells but not mouse cells, there was historically no good small-animal model for studying the virus in a living body. Humanized NSG mice filled that gap. When engrafted with human immune cells and then infected with HIV, these mice develop a pattern of viral replication and immune cell destruction that resembles what happens in people. Researchers can administer antiretroviral drugs and watch the virus get suppressed, then study whether it hides in latent reservoirs the way it does in human patients.⁵ Variant NSG strains, such as the B-NSG line developed in China, have also been validated for HIV work, with human T cells appearing in the mouse bloodstream as early as three weeks after transplantation.⁶

Limitations of the Standard NSG Model

For all their usefulness, NSG mice have real drawbacks that researchers have spent the last decade trying to work around. The most significant is graft-versus-host disease, or GVHD. When human immune cells are transplanted into an NSG mouse, those cells eventually recognize the mouse’s own tissues as foreign and begin attacking them. This creates a progressive inflammatory disease that limits how long the mice stay healthy and how long experiments can run.⁷ For short-term experiments, GVHD may not be a problem. But for any study that needs months of observation, such as evaluating the long-term safety of a cell therapy, GVHD confounds the results because you cannot tell whether the mouse is getting sick from the therapy or from the immune cells attacking its body.

This limitation has practical consequences for CAR T-cell research, one of the hottest areas of cancer immunotherapy. CAR T cells are engineered human immune cells designed to attack a patient’s cancer. Testing them in NSG mice makes sense in theory because the mice can host human cells, but the development of GVHD makes long-term safety assessment of CAR T effects unreliable.⁸ The disease the human cells cause in the mouse is not representative of what happens in patients receiving their own modified cells back, so researchers have to be careful about over-interpreting toxicity signals from these models.

Another limitation is that the human immune system that develops in a standard NSG mouse is incomplete. The mice tend to produce reasonable numbers of human B cells but relatively poor T-cell and myeloid cell development. This means the immune responses you can study are skewed toward certain cell types and may not reflect the full complexity of a human immune reaction.

Next-Generation NSG Strains

To address these shortcomings, researchers have developed modified versions of the NSG mouse that carry additional human genes. One approach is to knock in genes encoding human growth factors, which are signaling proteins that help human immune cells survive and mature in the mouse environment. Strains like NSG-SGM3 and MISTRG produce human cytokines that specifically support myeloid cells, the branch of the immune system responsible for innate defenses like inflammation and pathogen engulfment. These transgenic models have meaningfully improved the engraftment and function of human myeloid cells, enabling studies of innate immune responses that the standard NSG mouse handles poorly.⁹

Another recent advance involves engineering the mice to express human interleukin-6, a cytokine critical for sustaining human immune cells over long periods. One such model, called hNSGF6, showed significantly higher engraftment of human immune cells in the blood compared to standard NSG mice, with superior overall engraftment lasting over a year.¹⁰ This kind of long-term stability is exactly what fields like HIV cure research need, since studying viral latency and reactivation requires months of follow-up in a humanized host.

The pace of new strain development has been brisk enough that “NSG” is now as much a platform as a single mouse line. Researchers start from the standard NSG background and then layer on genetic modifications tailored to their specific question, whether that is better myeloid cells, longer-lived human T cells, or reduced GVHD.

Safety Considerations for Working with Humanized NSG Mice

One aspect of NSG mouse work that outsiders rarely hear about is the biosafety dimension. When you transplant human cells into a mouse and then infect it with a human pathogen like HIV, the result is a small animal carrying a live, replicating human virus. Standard laboratory mouse work already involves safety protocols, but humanized NSG mice require additional precautions because the pathogens they carry can, at least in theory, infect the people handling them. Institutions are expected to establish policies and guidelines that address these risks as part of their occupational health and animal care programs.¹¹ The practical upshot is that work with humanized NSG mice infected with human pathogens often takes place under heightened biosafety levels, with additional personal protective equipment and containment measures beyond what a typical animal facility requires.

NSG as Neurosonography

In a completely different corner of medicine, NSG stands for neurosonography, an ultrasound technique used primarily to image the brains of newborns. A portable ultrasound probe is placed against the fontanelle, the soft spot on an infant’s skull, and sound waves pass through to create real-time images of brain structures. The technique is fast, does not require sedation, involves no radiation, and can be performed right at the bedside in a neonatal intensive care unit.

Neurosonography is pivotal for rapid, point-of-care neonatal brain assessment, playing a key role in diagnosing conditions like bleeding inside the skull, fluid buildup in the ventricles, and brain injury caused by oxygen deprivation during birth.¹² It is especially valuable for premature infants, who are at high risk for a type of brain bleeding called intraventricular hemorrhage. In many NICUs, routine screening neurosonography is standard for babies born before a certain gestational age.¹³

When combined with Doppler ultrasound, which measures blood flow velocity, neurosonography can also evaluate the blood vessels feeding the brain and detect abnormalities in cerebral circulation.¹⁴ This Doppler capability adds a functional dimension to what is otherwise a structural imaging tool. Unlike MRI, which gives exquisite detail but requires the baby to be transported to a scanner and kept still (often under sedation), neurosonography trades some image resolution for speed, safety, and bedside convenience. For many clinical questions in neonatology, that trade-off is well worth it.

NSG as Necrotizing Sarcoid Granulomatosis

The rarest meaning of NSG in medical literature is necrotizing sarcoid granulomatosis, a lung disease so uncommon that many pulmonologists and pathologists have never encountered a case. NSG is characterized by clusters of inflammatory cells called granulomas, tissue death (necrosis), and inflammation of blood vessel walls, all occurring in the lungs.¹⁵ It sits at an awkward intersection between sarcoidosis, which also produces granulomas but without the blood vessel involvement, and vasculitis syndromes like granulomatosis with polyangiitis, which destroy blood vessels but produce a different pattern of tissue damage.

Part of what makes NSG so difficult to diagnose is that it mimics other diseases on imaging and even on biopsy. A chest CT may show lung nodules or masses that look suspicious for cancer or tuberculosis. Standard blood tests for vasculitis, including antibodies against certain white blood cell proteins, typically come back negative or show only low levels, which can send clinicians down the wrong diagnostic path. Definitive diagnosis usually requires a tissue biopsy showing the characteristic triad of granulomas, necrosis, and vasculitis together.

The disease appears across a wide age range, from childhood through the late sixties, with a median age around 42 years. Women account for roughly 60 percent of cases, and the disease is disproportionately reported in Caucasian patients.¹⁶ Fortunately, when correctly identified, NSG generally responds well to immune-suppressing medications, most commonly corticosteroids. Many patients improve substantially with treatment, and the prognosis is considered favorable compared to the more aggressive vasculitides it can resemble. The real danger lies in misdiagnosis: patients have undergone unnecessary lung surgery for suspected cancer, or received prolonged courses of antibiotics for suspected infection, before the true diagnosis was recognized.

How to Tell Which NSG Is Being Discussed

If you are reading a medical document and encounter “NSG” without further context, a few clues will tell you which meaning applies. In any paper mentioning mice, xenografts, humanized models, engraftment, or immunodeficiency, NSG refers to the mouse strain. In neonatal or pediatric radiology reports, particularly anything involving ultrasound of the brain, fontanelle, or ventricles, NSG means neurosonography. And in a pulmonology or pathology report discussing granulomas, vasculitis, or lung nodules, NSG likely refers to necrotizing sarcoid granulomatosis.

The mouse strain meaning overwhelmingly dominates the biomedical literature. A search of any major medical database will return hundreds of papers using NSG in the immunodeficient-mouse sense for every one using it in the neurosonography or granulomatosis sense. If the document you are reading is a research paper rather than a clinical report, the mouse is the safe bet. In clinical settings, though, context is everything, and the abbreviation’s meaning shifts entirely depending on the specialty of the physician using it.